Skip to main content

Table 1 Patient characteristics

From: Neurogranin and YKL-40: independent markers of synaptic degeneration and neuroinflammation in Alzheimer’s disease

  MCI-o Non-AD-D MCI-AD AD-D
Number of patients 29 14 13 39
Age, yr 69.4 [61–75] 65.1 [59–71] 73.3 [69–77] 72.5 [68–76]a
Sex, M/F 15/14 6/8 5/8 18/21
MMSE 27 [26–28] 20 [20–23]b 26 [25–28]c 21 [19–24]b
1-42, pg/ml 1262 [1014–1626] 1255 [997–1585] 638 [590–852] 796 [618–928]
1-40, pg/ml 15,393 [12,208–21,112] 13,332 [9303–22,989] 21612 [17,875–26,191] 20,803 [15,168–24,448]
t-tau, pg/ml 226 [158–246] 242 [189–320] 580 [487–789] 522 [403–708]
p-tau, pg/ml 44 [29–59] 46 [41–53] 92 [80–113] 99 [74–111]
  1. β-amyloid, p-tau phosphorylated tau, t-tau total tau, MMSE Mini Mental State Examination, MCI-o mild cognitive impairment not due to Alzheimer’s disease, young control subjects without dementia, non-AD-D dementia not due to Alzheimer’s disease, MCI-AD mild cognitive impairment due to Alzheimer’s disease, AD-D Alzheimer’s disease dementia
  2. The values represent the median [interquartile range]
  3. Differences between the groups were calculated using a nonparametric Kruskal-Wallis test followed by Dunn’s posttest. No p values were calculated for Aβ, t-tau, and p-tau, as the patients were selected according to these markers
  4. a p < 0.05 vs. non-AD-D
  5. b p < 0.001 vs. MCI-o
  6. c p < 0.01 vs. non-AD-D